title: Relationship Between Subretinal Hyperreflective Material Reflectivity and Volume in Patients With Neovascular Age-Related Macular Degeneration Following Anti-Vascular Endothelial Growth Factor Treatment.
abstract: OBJECTIVE
  To assess the relationship between subretinal hyperreflective material (SRHM) reflectivity and volume in patients treated with anti-vascular endothelial growth factor (VEGF) therapy for choroidal neovascularization secondary to exudative age-related macular degeneration (AMD).
  
  
  METHODS
  Data from 17 eyes of 16 patients with neovascular AMD undergoing anti-VEGF therapy were collected retrospectively. Optical coherence tomography (OCT) data were obtained using the Cirrus HD-OCT (Carl Zeiss Meditec, Dublin, CA) 512 × 128 macular cube protocol. Detailed manual segmentation was performed for each case using customized grading software.
  
  
  RESULTS
  The mean macular volume declined from 10.4 mm(3) at baseline to 9.6 mm(3) at 12 months. SRHM volume declined from 0.33 mm(3) to 0.12 mm(3), whereas reflectivity increased from 0.48 to 0.64 units (P = .012). SRHM reflectivity correlated positively with logarithm of the minimum angle of resolution (logMAR) acuity (r = .49, P = .04) but correlated with SRHM volume (r = -0.50, P = .04) only at baseline.
  
  
  CONCLUSIONS
  SRHM reflectivity, which correlated partially with SRHM volume, appears to carry independent information regarding disease activity. SRHM reflectivity may be useful for monitoring disease activity and response to therapy.
authors.forename: Wissam
authors.initials: W
authors.lastname: Charafeddin
authors.forename: Muneeswar Gupta
authors.initials: MG
authors.lastname: Nittala
authors.forename: Aldo
authors.initials: A
authors.lastname: Oregon
authors.forename: SriniVas R
authors.initials: SR
authors.lastname: Sadda
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000503:physiopathology; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D000069579:Ranibizumab / Q000627:therapeutic use; D012189:Retrospective Studies; D058471:Subretinal Fluid / Q000502:physiology*; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014792:Visual Acuity / Q000502:physiology; D057135:Wet Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab